Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY.
华盛顿州温哥华和纽约，2024年11月21日（全球新闻通讯）-- Absci公司（纳斯达克：ABSI），一家以数据为第一的生成性人工智能药物创造公司，今天宣布该公司将参加即将在纽约市举行的第36届年派杰投资医疗会议。
Absci's Founder & CEO Sean McClain is scheduled to participate in a panel discussion titled "The Promise of AI in Drug Development" on Thursday, December 5th at 2:00 p.m. Eastern Time.
Absci的创始人兼首席执行官肖恩·麦克莱恩定于12月5日（星期四）东部时间下午2点参与一场名为“人工智能在药物开发中前景”的小组讨论。
Interested parties may contact their Piper Sandler representative to request registration details for this live event.
有兴趣的各方可以联系他们的派杰投资代表，申请此直播活动的注册详情。
About Absci
关于Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Absci是一家将人工智能与可扩展实验室技术相结合的数据导向的生成AI药物研发公司，旨在更快地为患者创建更好的生物制品。我们的综合药物创新平台通过同时优化开发和治疗效益的多个药物特性，释放加速临床时间并增加成功率的潜力。凭借训练数据、人工智能和湿实验验证，我们可以每周筛选数十亿个细胞，从AI设计的抗体到湿实验验证的候选药物只需短短六周。Absci的总部位于华盛顿温哥华市，AI研究实验室位于纽约市，创新中心位于瑞士楚格。 平台可以解锁潜力，加速到达临床阶段的时间，并通过同时优化多种对开发和治疗效果重要的药物特性来增加成功的可能性。有数据用于训练，人工智能用于创建，湿实验室用于验证，我们可以每周筛查数十亿个细胞，使我们能够在短短六周内从人工智能设计的候选药物转变为湿实验室验证的候选药物。Absci的总部位于华盛顿州温哥华，我们的人工智能研究实验室位于纽约市，创新中心位于瑞士苏黎世。访问 ，以及 Twitter(@Abscibio)@absci，以及 Twitter(@Abscibio)@Abscibio）以及YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
投资者联系人
Alex Khan
财务与投资者关系副总裁
investors@absci.com
Media Contact
press@absci.com
媒体联系
press@absci.com
